if you are looking for research funding, apply today.

If your work is in need of funding, today - maybe the two of us should meet. Please go to www.lls.org to find out more.

someday is today

LEUKEMIA & LYMPHOMA SOCIETY*
fighting blood cancers
There's only one
Science
ScienceCareers.org
Science Careers
Advertising
For full advertising details, go to ScienceCareers.org and click.
For Employers, or call one of our representatives.

Tracy Holmes
Worldwide Associate Director
Science Careers
Phone: +44 (0) 1223 326525

EUROPE / INDIA / AUSTRALIA / NEW ZEALAND / Rest of World
E-mail: ads@science-int.co.uk
Fax: +44 (0) 1223 326532

Lucy Nelson
Phone: +44 (0) 1223 326527

Kelly Grace
Phone: +44 (0) 1223 326528

THE AMERICAS
E-mail: advertise@sciencecareers.org
Fax: 202-289-6742

Tina Burks
United States/Canada/South America
Phone: 202-326-6577

Marci Gallun
Sales Administrator
Phone: 202-326-6582

Online Job Posting Questions
Phone: 202-312-6375

JAPAN
Yuri Kobayashi
Phone: +81-(0)90-9110-1719
E-mail: ykobayasi@aaas.org

CHINA / KOREA / SINGAPORE / TAIWAN / THAILAND
Ruolei Wu
Phone: +86-1367-1015-294
E-mail: ruw@aaas.org

All ads submitted for publication must comply with applicable U.S. and non-U.S. laws. Science reserves the right to refuse any advertisement at its sole discretion for any reason, including without limitation for offensive language or inappropriate content, and all advertising is subject to publisher approval. Science encourages our readers to alert us to any ads that they feel may be discriminatory or offensive.

FACULTY POSITIONS MOLECULAR ONCOLOGY, IMMUNOLOGY AND VIROLOGY AT THE VACCINE AND GENE THERAPY INSTITUTE OF FLORIDA

The recently established Vaccine and Gene Therapy Institute of Florida (VGTI Florida) is pleased to announce faculty openings at all levels in the research areas of oncology, immunology and virology. The emphasis of VGTI Florida is on translation of original laboratory discoveries into innovative clinical treatments to improve human health. VGTI Florida is one of the internationally acclaimed research institutes invited to locate to Florida as part of a State-sponsored initiative to enhance biomedical research in Florida. Our research scientists enjoy outstanding benefits and salary with no state income tax, an intellectually stimulating work environment with new laboratories, high quality of life in affordable housing, and natural beauty of the sunny-Atlantic coast of Florida.

VGTI Florida occupies a new 100,000 sq. ft. state-of-the-art and LEED gold certified research building in Port St. Lucie just north of Palm Beach. Cutting-edge shared cores include Genomics, Flow Cytometry, Bioinformatics, and BSL3/ABSL3 containment facilities. VGTI Florida is ideally located in a Biotech cluster than includes many other top research institutes within a short driving distance. These include Scripps Research Institute of Florida, Torrey Pines Institute for Molecular Studies, and the Max Planck Florida Institute for Neuroscience, among others. VGTI Florida also has ongoing basic, translational and clinical collaborations with the University of Miami, Moffitt Cancer Center, and the Martin Health Systems.

We are seeking outstanding candidates with a track record of research excellence, as demonstrated by top peer-reviewed publications and competitive extramural grant funding. The major areas of focus are molecular oncology, human immunology and infectious diseases. Common themes across these areas include inflammatory responses, systems biology approaches, and therapeutics development. Primary emphasis for therapeutics includes but is not limited to vaccines, immunotherapy and gene therapy based strategies. Successful candidates must have a doctoral degree (PhD and/or MD) and substantial postdoctoral research experience. Preference will be given to established investigators currently leading vigorous research programs already well-funded by extramural grants and with publications in high-impact journals.

For more information please visit www.vgtifl.org. Qualified applicants should apply by submitting their curriculum vitae, bibliography, grant funding, and a description of their proposed research program to https://home.eace.adp.com/recruit/?id=3795661

VGTI Florida is an EEO/AAP Institution committed to recruiting, hiring, and promoting qualified minorities, women, individuals with disabilities, and veterans.

Systems Biology Faculty Position

The Peggy and Charles Stephenson Cancer Center at the University of Oklahoma Health Sciences Center is seeking applicants for a faculty position in Systems Biology. Rank and tenure eligibility will be commensurate with qualifications and experience. Stephenson Cancer Center members work in all aspects of cancer research, and the Center is promoting collaborative activities with an integrated systems biology approach among researchers within the Center and its affiliated institutions.

We seek exceptional candidates to lead a Systems Biology research focus at the Stephenson Cancer Center. Candidates should have demonstrated experience in combining experimental and computational approaches to elucidate the function, organization, and functional dynamics of the cancer genome. Candidates should be highly-motivated, have exceptional analytical skills, a strong interest in developing predictive cancer phenotypic models (predictive and/or prognostic biomarkers), and the ability and desire to work in a multidisciplinary team of cancer biologists, molecular biologists, clinical researchers, and oncologists. The selected candidate will be responsible for the integrative analysis of high-dimensional genetic and epigenetic data sets related to cancer genesis, progression, metastasis, and drug resistance with a focus on developing predictive diagnostic, therapeutic, and prognostic models and extending these experimental cancer models to clinical applications.

Applicants should have a Ph.D. or equivalent degree in a relevant area of cancer research including biochemistry, molecular biology, genetics, genomics, biomedicine, biophysics, bioengineering, chemistry, mathematics, computer science or statistics. Applicants should have relevant postdoctoral research training, demonstrated experience in interpreting cancer-relevant systems biology data sets, and a record of excellence in research as demonstrated through publications and funding. For additional information about the Cancer Center, please visit www.StephensonCancerCenter.org.

Applicants should electronically submit a curriculum vitae, a synopsis of professional goals and research interests, and arrange for at least three letters of recommendation to Danny Dhanasekaran, Ph.D., Deputy Director for Basic Research, Stephenson Cancer Center, at danny-dhanasekaran@ouhsc.edu. Confidential inquiries should be addressed to Danny Dhanasekaran, Ph.D., Deputy Director for Basic Research, Stephenson Cancer Center, at danny-dhanasekaran@ouhsc.edu.

The University of Oklahoma is an Equal Opportunity/Affirmative Action/Equal Access Employer.
Blurring the Lines Between Academic and Industrial Cancer Research

Once upon a time, there were only two career options for life scientists interested in cancer research: academia or industry. Each had its own culture defined by unique core objectives, and each had distinctive ways of managing systems of research, reputations, and rewards. Freshly minted postdocs may think they can still only do one or the other, but a new paradigm has emerged. Multidisciplinary collaborations across sector and scholarship lines are creating opportunities for ambitious cancer-fighting careers at the junction of the educational and business sectors. By Alaina G. Levine

Cancer research is broadly guided by the mission to find treatments and cures, but the way academic and industrial scientists conduct their investigations often diverge. One of the most notable differences is the driving force of the research itself. Academic research seeks to unveil a basic understanding of science, and is “deductive, granulosic, and mechanistic,” describes David Sidransky, director of the Head and Neck Cancer Research Division at Johns Hopkins University (JHU) School of Medicine in Baltimore, Maryland. There is freedom to explore theoretical ideas often with little concern about timelines.

Industry, on the other hand, is very goal-oriented, and even basic research is geared towards being translational, says Sidransky. Priority is placed on developing commercializable cancer therapies. Whereas in academia a typical investigation might entail determining “the affinity of an antibody to its receptor and the effects on signaling,” the commercial question, he clarifies, would focus more on “how antibody binding affects other targets for toxicity and on the overall cellular clinical response to the antibody, rather than on the details of the signaling pathways.”

Scaling up the technology and manufacturing multiple versions of a product are discussed early on in industrial projects, says Scott Eliasof, vice president of research at Cerulean Pharma, a Cambridge, Massachusetts-based company with a focus on designing tumor-targeted nanopharmaceutical therapies. “Industry scientists focus more on the nuts-and-bolts of moving a project into the clinic, a skill set not often found in academia.”

“Industry and academia have two different motives for research,” says Benjamin Y. Clark, an assistant professor in the Maxine Goodman Levin College of Urban Affairs at Cleveland State University, in Ohio. The private sector is motivated by product development and profit, whereas academia is motivated by intellectual curiosity, he notes. “They each have a different bottom line and financial support comes from different places.”

It is no surprise that Big Pharma won’t fund a decade’s worth of research on a molecule that can’t be molded into a cancer therapy. “In the private sector you are time-constrained and not resource constrained, while it is the opposite in academia,” says Jennifer Malin, an associate clinical professor at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), and the managing medical director of oncology for WellPoint, an Indianapolis, Indiana-based parent company of 14 health insurance plans.

Indeed, resource availability and diversity are cited differences between the two realms. In industry, especially in large, older corporations, resources are often plentiful. “Big Pharma has an almost infinite amount of resources and lots of expertise,” says Eliasof. However, while a smaller company like his, which only has 33 employees, may not have a wealth of financial resources from which to partake, there is more opportunity to affect agendas and decide company priorities, he notes. This element in particular can be very appealing to academic scientists pondering a move to industry.

“Depending on the type of cancer research, [scientists] can become quite siloed in academia,” says Malin. “But it’s impossible to work in silos in the private sector.” Companies rely on collaboration across disciplines such as cancer biology, oncology, cellular biology, chemistry, and biotechnology. “Industry scientists often work closely with [continued>
Focus on Careers
Cancer Research Careers

“Young people today...need to learn that the old cowboy way of doing science where you work by yourself is gone.”
—Linda H. Malkas

Oncologists who treat patients, and can therefore have a better understanding of what is needed to make a difference in cancer patients’ lives,” says Eliasof. “To me, this is one of the most important differences between industry and academia and, in fact, is why I moved to industry.”

The interdisciplinary nature of the private sector extends beyond research. Scientists often end up working with professionals in regulatory affairs, quality control, and even marketing. “It spans the whole continuum of disciplines, whereas in academia ‘multidisciplinary’ means it spans the sciences only,” says Malin, although, more and more, this is changing.

Team-based projects are a mark of industrial cancer research. “The notion that you can work in a larger team and provide improved value for the patient is a central goal for our company,” says Samuel Levy, chief scientific officer of Genomic Health, a molecular diagnostics oncology company based in Redwood City, California. Teamwork is essential because in industry “people are evaluated by how well your team does,” says Malin. In fact, training to be a good manager is often a fundamental part of serving as a researcher in industry, she continues.

And then there’s the issue of recognition. Eliasof sums up the spirit of each arena: “Academic scientists are rewarded for publishing novel, cutting-edge research,” he explains, “but the novelty may or may not be practical at the end of the day. In contrast, industry scientists are rewarded for identifying scientifically and financially pragmatic projects and bringing them to the clinic, where they can help cancer patients.”

Mastering Coveted Skills

In most cases, many of the skill sets are the same for cancer researchers in academia and industry, says Linda H. Malkas, who serves as the deputy director of basic research, co-leader of the molecular oncology program, and a professor of molecular and cellular biology at City of Hope (COH) in Duarte, California. Leadership potential, creativity, and oral and written communication skills are qualities that both academic and industrial scientists can master in their own environments.

“If you look at the best academic scientists, they are great storytell-
ers,” says Eliasof. Researchers in industry also have to be able to effectively articulate missions and complex scientific problems, although their stakeholders and audiences tend to be more diverse.

Eliasof expresses concern that team building, a universally coveted skill, sometimes doesn’t manifest itself well in universities. “When I bring people in right from academia sometimes they haven’t learned how to function efficiently on teams,” he explains.

And there are other skills that might not be as easy to learn while in an academic setting. Malkas attests that scientists can hone special skills by working alongside clinicians and patients, which is an opportunity that university and business enterprises don’t always provide. At City of Hope, early career scientists learn to think translationally and to always consider how they can apply their knowledge to affect cancer treatment, she says.

Trends and Shifts in Cancer Research

But overall, the culture within both academia and industry is starting to change. “Work environments are becoming more diverse, especially in academia,” says Clark. “If researchers want to get anything done, they have to work across disciplines.” Jay Strum, president of G1 Therapeutics, a Chapel Hill, North Carolina-based enterprise that focuses on small molecule therapies, regularly collaborates with university researchers and has noticed, for example, that statisticians are playing larger roles in academic cancer research teams. “The trend is moving towards better designed experiments [that incorporate] statistics earlier on,” he says.

Moreover, initiatives like National Science Foundation- and National Cancer Institute-funded research centers at universities, which emphasize cross-disciplinary projects, also “break down barriers between academia and industry, and enable us to bring cures and therapies to the market faster,” says Clark.

In fact, “to a certain extent, the lines between academia and industry are blurring,” says Strum. Hybrid institutes are being launched or expanded to harness the collaborative power that flourishes when industrial and academic scientists work together. COH is similar to an academic setting, yet students and postdocs are able to interact with clinicians, physicians, and sometimes patients, explains Malkas. Ph.D. committees are much more diverse compared with strictly academic institutions. For example, a standard cancer research dissertation committee at COH could include experts in bioinformatics, gene expression, and proteomics, whereas at a university, “the committees are more homogeneous,” she says.

These hybrid institutions play another important role since “the huge, prohibitive costs associated with the clinical development of very early and risky research make it difficult for industry to pursue truly novel and unique molecular targets for cancer therapy, diagnosis, or intervention,” describes Malkas. Organizations like COH recognize the value in this type of science. COH has “set up the infrastructure and resources to absorb the risk of early development...of discoveries not only for our own investigators, but for other institutions as well,” she says.

Universities are also taking the lead in designing new centers that aggregate research goals and accelerate new discoveries to market. The Broad Institute, where Eliasof worked before coming to industry, and the New York Genome Center are two examples. But even within typical academic departments, scholars are becoming savvier...continued>
The Peggy and Charles Stephenson Cancer Center (SCC) at the University of Oklahoma Health Sciences Center invites applications for faculty positions. Rank and tenure eligibility to be commensurate with qualifications and experience. Interested applicants should have a demonstrated record of sustained, peer-reviewed funding and publications, with preference given to active NCI funding.

The SCC is Oklahoma’s only academic cancer center. It has a well-developed and supportive infrastructure and over 120 members from the University of Oklahoma (OUHSC, OU Norman, OU Tulsa), the Oklahoma Medical Research Foundation and Oklahoma State University. The SCC places a high priority on promoting translational research that moves research ideas into clinical applications. Position applicants should have demonstrated research aligned with one of the following four SCC research programs (and research foci):

- Basic Cancer Biology (epigenetics/chromatin regulation; tumor microenvironment; tumor-stromal cell interactions; angiogenesis; metastasis; tumor initiating cells/cancer stem cells)
- Experimental Therapeutics (molecular targeted therapies; gene and drug delivery; nanomedicine; high-throughput drug discovery; cancer imaging; Phase 0 & Phase I trials)
- Gynecologic Cancers (angiogenesis; drug resistance)
- Cancer Health Disparities (special populations, with emphasis in American Indian; health outcomes; tobacco research)

With the support of a recently completed $67 million fundraising campaign and institutional development grants of over $30 million (cancer research) and $5 million (tobacco prevention and control research) from the Oklahoma Tobacco Settlement Endowment Trust, the SCC has launched a major initiative to recruit 20 cancer-focused researchers over the next four years. SCC Shared Resources include a Biospecimen Acquisition Core and Bank, Molecular Imaging Core, Cancer Functional Genomics Core, Cancer Tissue Pathology Core, Biostatistics Core, Special Populations Core, and Proposal Services Core. The SCC has a large clinical trials research program and a rapidly expanding Phase I Program.

Applicants must possess a PhD, MD, or MD/PhD in a relevant discipline and have a demonstrated potential for excellence in research. Selected candidates will have an appointment in an academic department as well as the SCC. For additional information, please visit www.stephensoncancercenter.org.

Applicants should provide electronic copies (only) of a cover letter stating area of expertise and qualifications, synopsis of professional goals, research interests, curriculum vitae, and e-mail addresses for three references to CancerResearch@ouhsc.edu. Confidential enquiries may be addressed to Danny N. Dhanasekaran, PhD, Deputy Director for Basic Research, at danny-dhanasekaran@ouhsc.edu.

The University of Oklahoma is an Equal Opportunity Employer.
about incorporating industrial partners earlier in the research and grant writing process, and university tech transfer offices are getting better at engaging scientists with intellectual property issues, notes Strum.

New discoveries about the nature of cancer, and new tools and techniques to study its growth and demise, have fueled many cross-sector alliances. For example, academic and industrial scholars must work together to identify biomarkers using high throughput analysis, if they are to move the outcomes to the clinic faster. Genomics is useful for both studying cancer and finding treatments, which additionally encourages interdisciplinary collaboration, says Levy. “Genomics information obtained through analyzing nucleic acid sequences have revolutionized the way we interrogate and investigate clinical samples to answer specific questions about the role of genomics in patient care,” he explains. “We are definitely seeing a broad need in medicine to find ways of using genomics techniques to make a clinical difference.”

André Goy, chief of the Lymphoma Division and director of the Tissue and Tumor Bank at the John Theurer Cancer Center at Hackensack University Medical Center (UMC), notes that in both academic and industrial labs there is more of a spotlight on understanding cancer cell biology using novel therapies, or “precision medicine” utilizing biomarkers identified through genomics. “The next generation of physicians and scientists will be exposed early on to this progress as we evolve towards a redefinition of the classification of cancers—not only based on the organ of origin but on shared molecular characteristics, hopefully providing a rationale for treatment decisions in a growing number of cancer patients,” he suggests. Furthermore, with an expanding number of scientists working on both sides of the fence, Goy is seeing a heightened interest in the business of medicine, with an increased number of scientists and physicians pursuing MBAs. “Many factors are reshaping the field of cancer care,” he clarifies. The research techniques, technology, economics, and molecular diagnostics are just some of those moving pieces. Generally “researchers in any environment will have to become more outcome based,” says Goy.

Advice for Scientists in the Changing Landscape

One piece of advice that these experts keep emphasizing is that there is no set course for a career in cancer research. Scientists can now choose industry, academia, a hybrid, or a combination of any of these. Just as the field of cancer research is becoming more diverse and interdisciplinary, so is the profession.

“It’s not like once you make a choice, you’re stuck with that choice forever,” says Eliasof. “You can move from academia to industry and vice versa,” although he admits it can be harder to move from a company back to a university because of the lack of demonstrable publications. But there is a way to make a company-to-university transition easier and more efficient: “Keep interacting with your colleagues in academia so they know about you,” advises Nalân Utku, the managing director and co-founder of CellAct, a small German cancer research company who has also spent considerable time in academia.

But the academic setting is experiencing a metamorphosis in more ways than one. For instance, “academia is starting to recruit from industry more,” says Eliasof. And “the choices of direction of cancer research in academia are not as broad as they used to be,” notes Clark. “Academic research is being driven more and more by where the money comes from.”

As more researchers realize that cross-disciplinary and cross-sector investigations are good for science and medicine, leaders predict there will be more collaboration between industry and academia. “We’re discovering that we need each other,” says Malkas. “Young people today...need to learn that the old cowboy way of doing science where you work by yourself is gone.” Indeed, the majority of the time “it’s about ‘group science’ for groundbreaking research,” echoes Clark.

To prepare for a career in cancer research, scientists need a multidimensional skill set to tackle questions from different fronts. “Think big and bold, but focus,” advises Goy. “The old rules of research still apply, but the way we are going to do things will with no doubt change dramatically in the coming years.” Academic scientists should get to know clinicians and their work with patients, and learn business skills. To further enhance one’s marketability, develop a good understanding of data analysis and computational biology—skills which are becoming more and more coveted as technology improves and the amount of data being analyzed increases exponentially, notes Giulio Draetta, director of the Institute for Applied Cancer Sciences (IACS) and professor in the Department of Genomic Medicine at the University of Texas MD Anderson Cancer Center.

Above all, attitude is key. “Whether you are in industry or academia, research is a discipline that’s bound to give you 99% failure,” says Draetta. “You have to believe in yourself.”

Alaina G. Levine is a science writer and science careers consultant/speaker based in Tucson, AZ

DOI: 10.1126/science.opms.r1300131
Faculty Positions in the Genetics of Aging at The Jackson Laboratory

The Jackson Laboratory is an independent, nonprofit, biomedical research institution with more than 1,400 employees, and three campuses located in Bar Harbor, Maine, Farmington, Connecticut and Sacramento, California. The Laboratory's mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health. We are actively expanding our research program in the genetics of aging and recruiting faculty members with a research focus in this field, especially those centered on cellular mechanisms of aging.

We seek scientists with Ph.D., and/or M.D. degrees, who have completed postdoctoral training and have a record of research excellence. Candidates should have the ability to develop a competitive, independently funded research program that takes advantage of the mouse as a genetic model for understanding human biology, diseases of aging and longevity.

Open positions are:

Program Director — In addition to his/her research program, this experienced leader in the field of aging will promote and coordinate the activities of The Jackson Laboratory's aging program, and spearhead fund-raising efforts in this research area. The Director will lead The Jackson Laboratory Nathan Shock Center of Excellence in the Basic Biology of Aging. The Center focuses Jackson Laboratory researchers’ diverse expertise in biology and genomics on problems of aging, leading to enhanced resources for the aging research community and a better understanding of the molecular mechanisms at work in lifespan and healthspan.

Apply to position #3636.

Assistant, Associate or Full Professor — Aging Genetics Faculty members will run independent labs for relevant biomedical research on the biology of aging and age-associated diseases, will participate in The Jackson Laboratory's aging programs, and will mentor graduate students, postdoctoral associates and research staff, in a collaborative and supportive environment.

Apply to position #3635.

Applicants must apply online by submitting a curriculum vitae and a concise statement of research interests and plans as one document, to www.jax.org/careers, referring to position #3635 or #3636. In addition, please arrange to have three letters of reference sent to: facultyjobs@jax.org.

The Jackson Laboratory is an OEO/AA Employer.

600 Main Street, Bar Harbor, ME, 04609 | www.jax.org

Faculty Position in Developmental Biology and Regenerative Medicine

The Center for Developmental Biology and Regenerative Medicine in the Seattle Children’s Research Institute and Department of Pediatrics at the University of Washington School of Medicine seeks outstanding scientists (up to three positions) to be appointed full-time, without tenure, at the Assistant, Associate or Professor level. Applicants should possess Ph.D., M.D., or M.D., Ph.D. degrees. Areas of interest are broad; these include human genetics, model organism genetics, stem cells and regeneration, and systems level analyses of pathways involved in disease and development. The successful applicant will enjoy a competitive start-up package, and excellent space and state-of-the-art facilities in the Research Institute, which is near the University of Washington South Lake Union Campus, the Fred Hutchinson Cancer Research Center, and the Institute for Systems Biology. He or she will be appointed as faculty at the University of Washington, and will be part of a Center with diverse interests and expertise.

Please send a CV, a 2-3 page description of research interests and plans, and contact information for 3 letters of recommendation to:

Mark Majesky, Ph.D., and David Beier, M.D. Ph.D.,
search committee co-chairs
c/o Wendy Kramer, Business Manager
Center for Developmental Biology and Regenerative Medicine
Seattle Children’s Research Institute
1900 Ninth Avenue, MS: C9S-5
Seattle, WA 98101-1309
wendy.kramer@seattlechildrens.org

University of Washington faculty engage in teaching, research and service. In order to be eligible for University sponsorship for an H-1B visa, graduates of foreign (non-U.S.) medical schools must show successful completion of all three steps of the U.S. Medical Licensing Exam (USMLE), or equivalent as determined by the Secretary of Health and Human Services. The University of Washington is building a culturally diverse faculty and strongly encourages applications from female and minority candidates. The University is an Equal Opportunity Affirmative Action Employer.

Stanford University Medical Center

Melanoma Investigator

Assistant Professor, Associate Professor, or Professor

The Division of Oncology in the Department of Medicine at Stanford University is recruiting a melanoma physician investigator. The faculty position is at the Assistant, Associate or Full Professor level in either the University Tenure Line (UTL) or the Medical Center Line (MCL), and the successful candidate should be an accomplished laboratory or clinical investigator. Faculty rank and line will be determined by the qualifications and experience of the successful candidate.

The predominant criterion for appointment in the UTL is a major commitment to research and teaching. The major criteria for appointment for faculty in the MCL shall be excellence in the overall mix of clinical care, clinical teaching, scholarly activity that advances clinical medicine, and institutional service—appropriate to the programmatic need the individual is expected to fulfill.

The successful candidate will be expected to build a strong clinical/translational research program, teach fellows, and participate in the melanoma oncology clinics of the interdisciplinary Pigmented Lesion and Melanoma Program. Candidates should have an MD or MD/PhD and be board certified or board eligible in Medical Oncology and/or Hematology. The Division of Oncology benefits from an outstanding scientific and clinical environment at Stanford, including active collaborations with the basic science departments and the Stanford Institutes, including the Stem Cell Institute, the Immunity, Transplantation, and Infection Institute, and the Cancer Institute. For more information about existing programs, see http://cancer.stanford.edu/skincancer/expertise.html.

Candidates should submit a detailed letter of interest and curriculum vitae to: Margaret Wootton, Melanoma Search Committee, Division of Oncology, Stanford University, 265 Campus Drive, Room G3141, Stanford, CA 94305-5463; email: margaret.wootton@stanford.edu

Stanford University is an Equal Opportunity Employer and is committed to increasing the diversity of its faculty. It welcomes nominations of and applications from women and members of minority groups, as well as others who would bring additional dimensions to the university’s research, teaching and clinical missions.
Multiple Tenured Faculty Positions at Nankai University
Chemistry and Material Science Divisions

With well internationally established recognition, the Chemistry and Material programs at Nankai University are inviting the applications for full-time tenured faculty positions of academic ranks of Assistant/Associate/full Professor, to be appointed in Chemistry and Material divisions of Nankai University. The positions are available immediately. Applications will be evaluated by the faculty search committee upon receipt until the positions are filled.

Nankai University

As one of the top elite universities and comprehensive one in China, Nankai University has wide and international recognition. It is located in Tianjin City, one of the largest cities in China and connected with Beijing by 30 min high speed train. The Chemistry division of Nankai has been ranked as one of the top ones in China.

Qualifications

Candidates in all Chemistry and Material majors are welcomed. Successful candidates are required to have Postdoc/faculty experience and strong proven academic records.

Salary/Benefits

Successful candidates will be provided with a sizable start-up package including competitive research funding, salary, initial housing/rental funding, and lab space. Successful candidates are also encouraged/supported to apply for various national programs such as “Thousand Talent Plan” and “Changjiang Professorship” programs.

To Apply

Candidates are encouraged to initially email their CV with the publication list AND a one-page statement to Prof Chen at email yschen99@nankai.edu.cn.

Ocean Research Center of Zhoushan, Zhejiang University

Ocean Research Center of Zhoushan, Zhejiang University is a research institution in Zhoushan City, Zhejiang Province, China, which is set up by Zhoushan government and Zhejiang University in 2009. Multiple positions for senior talents are open in following areas:

- Marine sciences, including physical oceanography, marine chemistry, marine biology, marine geology etc.
- Marine engineering, including shipbuilding, mechatronics, environment, information, energy etc.
- Marine policy and culture.

Applicants should have strong research profile and potential capacity to conduct innovative research in these areas and have at least 3 years working experiences in first-class universities, research institutes or enterprises. The center provides state-of-the-art research facilities and strong supporting staffs. Competitive start-up support, salary and benefits will be offered according to individual qualification and experience.

Please submit your full CV, the cover letter and your future plan to Ji Wenzhu at ajiwenzhu@yahoo.com.cn or call 86-(0580)-2186309. The positions will be open until they filled by appropriate candidates.
The Oswaldo Cruz Foundation (Fiocruz; [www.fiocruz.br](http://www.fiocruz.br)), an institution affiliated to the Brazilian Ministry of Health, is building the Center for Technological Development in Health (CDTS for its acronym from Portuguese). Following its inauguration in 2014, the buildings of the CDTS will host technological platforms, animal experimentation and flexible laboratories in 20,000 m² of state of the art facilities. The CDTS will provide the necessary infrastructure to fully implement the spirit of the Brazilian 2004 Law on Innovation, which encourages partnerships between public and private sectors. Fiocruz has mandated the CDTS to establish and work in collaboration with other centers of scientific excellence for the joint development of health products against diseases that are of epidemiological or economic importance to Brazil, especially neglected tropical diseases.

To mobilize and strengthen the human resources needed, Fiocruz and CAPES (an agency of the Ministry of Education) have dedicated the following fellowships for PhDs to collaborate with the CDTS. In the long term the program aims to establish sustained partnerships between Fiocruz and other leading institutions, both public and private.

1. **Post-doctoral Program**

   Open to Brazilian candidates who have completed their PhD/DSc work and are willing to perform post-doctoral training at public or private institutions in Brazil or abroad with a commitment to join a CDTS project upon the completion of the program.

   - **RD-BR:** up to 20 (twenty) Post-doctoral Fellowships to train young Brazilian scientists in public or private R&D centers of excellence in Brazil (maximum 48 months);
   - **PD:** up to 10 (ten) Post-doctoral Fellowships to train young Brazilian scientists at institutions abroad (maximum 12 months).

2. **Visiting Professor Program**

   Open to scientists and technology management professionals at PhD/DSc or equivalent level, from institutions of public or private sectors, with proven experience and outstanding achievement. Citizens from countries that maintain a diplomatic relationship with Brazil are eligible. The program is available for stays lasting from one week to one year and can be renewed. The work will be conducted at Fiocruz. Stipends will be determined based on experience.

   - **PD-ES:** up to 10 (ten) Visiting Professor Fellowships to support senior Brazilian scientists to conduct research abroad (maximum 18 months);
   - **PVE:** up to 10 (ten) Visiting Professor Fellowships to support foreign professionals for collaboration on projects within the CDTS and to participate in Fiocruz graduate programs (maximum 48 months);
   - **PVNS:** up to 10 (ten) Visiting Senior Professor Fellowships to support senior Brazilian scientists to collaborate on projects within the CDTS and to participate in Fiocruz graduate programs (maximum 48 months).

**Skills areas:**

1. **Research and Development:** Structure and function of macromolecules (genomics, proteomics, glycomics, computational biology, bioinformatics) and small molecules (lipidomics, metabolomics); Disease-associated biological networks; Expression systems and fermentation (bacteria, yeast, mammalian, plant); Development of animal models (transgenics and knock-out/in); Bioprospecting and drug discovery; Nanotechnology; Biostatistics; Prevention/control of infectious diseases;

2. **Technology Development:** Molecular biomarker discovery and production; synthesis of peptides & DNA; Aplamer design; Production and purification of monoclonal antibodies and recombinant proteins; Pre-clinical studies including toxicology; Clinical pharmacology; High content screening; Bioassays; Libraries of chemicals and biologicals; Drug design, in silico modeling; Chemistry/Biology, Manufacturing and Control (CMC/BMC); Standard Operating Procedures (SOPs); Animal experimentation; Biosafety facilities

3. **Technology Management:** Intellectual property rights and patent landscape; Regulatory affairs - liaison with Regulatory Authorities, development of Drug Master Files (DMF), compilation and submission of dossiers (IND or NDA); Technology transfer;

4. **Business Development:** Pipeline strategy and portfolio management; Business planning; Partnership strategy; Negotiation of public-private alliances and partnerships; Management of established alliances and partnerships; Fund raising; Health technology assessment and economic evaluation in health;

5. **Capacity building:** multidisciplinary cross-cutting capacity strengthening for R&D, technology development, technology management and business development (for individuals, institutions and networks), built on national and international partnerships with industries, PDPs, regulatory agencies and global health initiatives for disease control; including risk management, knowledge management, research ethics, clinical development, product delivery and implementation research.

**Selection criteria:**

Priority will be given to eligible candidates who can prove:

1. **Strong support for their applications from the institution where the Post-doctoral stay will be performed or where the Visiting Professor is affiliated, including willingness to engage in long-term collaboration with Fiocruz after the training or visiting period;**

2. **Relevance of the training or R&D activities to Fiocruz objectives and goals;**

3. **Previous experience pertinent to the CDTS project and its long-term goals.**

Candidates will be selected by a six-member expert panel nominated by Fiocruz and CAPES. The program will run until 2016.

For further information or to express interest, contact: *Center for Technological Development in Health (CDTS)*

Oswaldo Cruz Foundation (Fiocruz) - Ministry of Health of Brazil - Campus de Manguinhos – Av. Brasil 4.365 – Rio de Janeiro, RJ – CEP 21.040-900 – Brazil – E-mail: ccdts@fiocruz.br (with copy to anaelisa@cdts.fiocruz.br)

[www.fiocruz.br](http://www.fiocruz.br)
Tenure-Track Investigator(s)

The Intramural Research Program (IRP) of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) in the Department of Health and Human Services (DHHS) is recruiting outstanding tenure-track investigators (M.D., Ph.D., or M.D./Ph.D) in research areas relevant to musculoskeletal biology or diseases. Candidates should have a PhD or MD; postdoctoral experience; and a strong record of research accomplishments.

Applications should be submitted to:

Ms. Margaret Vincent – RE: Musculoskeletal Initiative Building 31 Room 4C-12
9000 Rockville Pike, Bethesda MD 20892
Email: vincentm@mail.nih.gov

DHHS and NIH are Equal Opportunity Employers.

The NIH is dedicated to building a diverse community in its training and employment programs.

The HHS and NIH are Equal Opportunity Employers.

Assistant, Associate, or Full Professor of Neurobiology

Institute of Molecular Medicine and Genetics

Georgia Regents University

Georgia Regents University (GRU) is accepting applications for an Assistant, Associate, or Full Professor position (tenure-track or tenured) in the Institute of Molecular Medicine and Genetics. Candidates should have a PhD or MD; postdoctoral experience; interests in neural development, synaptic plasticity, or disorders of the central or peripheral nervous systems; and a strong record of research accomplishments. Faculty members are expected to establish or have cutting edge research programs and participate in teaching medical and graduate students. GRU is a state supported academic medical center located in a historic city with outstanding recreational and lifestyle opportunities.

Please apply for this position at www.georgiahealth.edu/facultyjobs and reference position #9347. Submit a CV, statement of current/future research interests, and contact information for three references to: Dr. Darrell Brann, c/o Deenie Cerasuolo (dcerasuol@gru.edu). Applications will be received until the position is filled.

GRU is an EEO/AA/Equal Access Employer.
Postdoctoral Scholars

The University of Calgary is a vibrant community of scholars committed to discovering new knowledge and translating discoveries into applications that will benefit our society and the global community. Within this exciting research enterprise, the Faculty of Medicine is well positioned to improve health outcomes through innovation in research and education as well as meeting the health challenges of a growing society. With the launch of the University’s Eyes High strategic vision, we are set to make ground-breaking contributions and invest in our future as leaders with a social responsibility to bring benefit to our society through excellence, integrity, and innovation. The University’s Rising Star program recognizes the importance of postdoctoral fellows whose skills and perspective will define our success and shape our collective vision. For more information please visit http://www.ucalgary.ca/risingstars/postdoc

The Faculty of Medicine invites applications for new postdoctoral scholars in the strategic priorities of Brain and Mental Health, Infections, Inflammation and Chronic Disease, Engineering Solutions for Health and Human Dynamics in the Changing World with the following researchers:

**Electron tomography and super resolution light microscopy, to examine the basis of transcription at the molecular level in real time.**
Supervisor: Matthias Amrein, James McGhee, Karl Riabowol

**Health services research within the area of integrative oncology: integrating and evaluating complementary therapies and education for cancer patients and health care providers.**
Supervisor: Linda Carlson

**Autologous stem cell therapy for skin regeneration and improved functional outcome following split thickness skin grafting.**
Supervisor: Vincent Gabriel (Jeff Biernaskie)

**Imaging the immune system to understand the molecular mechanisms underlying host response.** Supervisor: Paul Kubes

**Mechanisms of genomic instability in yeast and mammalian systems.** Supervisor: Susan Lees-Miller

**Structure and function of the NOD-like receptor (NLRP) subfamily of innate immune receptors in the pathogenesis of non-microbial/ sterile inflammation.** Supervisor: Justin MacDonald

**How is household food insecurity defined and socially constructed as a policy problem in Canada.** Supervisor: Lynn McIntyre

**Assess mechanisms of inflammation in the gut and mechanisms of disease recovery and tissue resolution after injury.**
Supervisor: Derek Mckay

**Glial and Schwann cell therapy based approaches to improve axonal regeneration and remyelination for nerve and spinal cord repair.**
Supervisor: Raj Midha

**Effects of Regular Exercise on Cerebrovascular Reserve in Older Adults: Role in the Prevention of Age-Related Cognitive Decline.**
Supervisor: Marc Poulin

**Regulation of Cerebral Blood Flow in Obstructive Sleep Apnea.**
Supervisor: Marc Poulin

**Nanomedicines for the treatment of autoimmunity.**
Supervisor: Pere Santamaria

**Biochemistry of EMMPRIN and extracellular matrix molecules.**
Supervisor: V. Wee Yong

**To advance the neuroscience of axon regeneration.**
Supervisor: Doug Zochodne

**Impact of perinatal environmental exposures, including exposure to neurotoxics and psychological stress, on children’s neurodevelopment and behaviour.** Supervisor: Deborah Dewey

**Developing non-invasive assessment methods for bone strength and fracture healing using state-of-the-art high resolution computed tomography imaging.** Supervisor: Steve Boyd

Applicants should clearly specify the supervisor/project that they are applying to including their curriculum vitae, a letter outlining their research experience, their vision for the research, and the contact information for at least three referees to the Faculty of Medicine, University of Calgary at medgrant@ucalgary.ca by April 20, 2013. Consideration of applications will continue until the positions have been filled.
The theory and practical techniques for efficient crop irrigation, NWAFU has established Special Professorships in the following academic areas and invites highly talented and motivated candidates to apply:

I. Academic areas with job openings
- Maize genomics and molecular breeding,
- Vegetable molecular breeding,
- Tree genetics and breeding,
- Animal molecular breeding,
- Apple genomics,
- Functional genomics of plant nutrition,
- Crop functional genomics,
- Soil chemistry,
- Soil erosion prediction modeling,
- Animal cell engineering and embryo engineering,
- Pathogenic microorganisms of animals,
- Plant stress biology,
- Material cycling in watershed ecosystem,
- Structural optimization and structure-function relationship of biologically active natural substances,
- Food safety,
- Theory and practical techniques for efficient crop irrigation,
- Hydrological modeling theory and methods,
- Agricultural machinery and technology,
- Forestry economic theory and policy,
- Contemporary sociological theory and research methods.

II. Applicant Eligibility
- 2.1 Ph.D. degree in related disciplines. Under 45 years old for applicants in natural sciences and under 50 years old for those in social sciences.
- 2.2 Holding an assistant professor or more senior position for international applicants. A rank of full professor or equivalent for domestic applicants.

III. Benefits and Salary
- 3.1 Entitlement of full professorship and supervision of Ph.D. students.
- 3.2 A minimal startup funding of ¥3 million for candidates in natural sciences and ¥1 million for those in social science.
- 3.3 An apartment and a ¥0.3 million household allowance will be provided. Ownership of the apartment will be transferred to the faculty members after serving the university for ten years.
- 3.4 In addition to regular salary and benefits, qualified applicants will be compensated with an annual allowance of ¥0.1-0.5 million. International candidates will receive a minimal annual salary of ¥0.6 million.
- 3.5 Spousal hiring will be accommodated.

IV. Application Procedure
- 4.1 Applicants should provide:
  - An English version of curriculum vitae with lists of publications, research interests and professional titles and activities;
  - A statement of research accomplishments and future teaching and research plan;
  - PDF copies of academic transcripts, diploma and degree certificate, five representative papers or books and documents for funded projects, awards, patents and keynote speakers at international conferences, etc;
  - Three recommendation letters with referees’ e-mails and telephone numbers.
- 4.2 NWAFU will conduct a preliminary screen and invite eligible candidates to Yangling for an interview and campus visit. The selected candidates need to sign a contract with the university. See our Chinese ad at http://rbw.nwsuaf.edu.cn
- In addition, NWAFU the Global Experts Program and the Youth Global Experts Program are also open to applications from China and abroad. Please visit our website: http://rbw.nwsuaf.edu.cn for more information.

V. Contact
- Address: No. 3 Taicheng Road, Yangling, Shaanxi Province, 712100 China.
- Contact Person: Chen Xiaoyan
- Tel: +86-29-87082855 - 87082577, Fax: +86-29-87082855
- E-mail: renaizh@nwsuaf.edu.cn, renaizh@gmail.com
- The university’s website: http://www.nwsuaf.edu.cn

The EGL Charitable Foundation invites you to apply to the Gruss Lipper Post-Doctoral Fellowship Program

Eligibility
- Israeli citizenship
- Candidates must have completed PhD and/or MD/PhD degrees in the Biomedical Sciences at an accredited Israeli University/Medical School or be in their final year of study
- Candidates must have been awarded a postdoctoral position in the U.S. host research institution.

Details regarding the fellowship are available at www.eglcdf.org

PRIZES

The 2013 (29th) International Prize for Biology

Calling for Nominations

This year’s research field: Biology of Evolution

Please access to: http://www.jsps.go.jp/english/e-biol

Deadline: May 17, 2013

- The International Prize for Biology was established in 1985 to commemorate the sixty-year reign of Emperor Showa and his lifetime devotion to biological research.
- The Prize is awarded each year to an individual who has made an outstanding contribution to the advancement of basic research in a field of biology.
- The Prize shall consist of a medal and a prize of ten million yen.

Recent Years Prize Winners

2012 Dr. Joseph Altman (Neurobiology)
2011 Dr. Eric H. Davidson (Developmental Biology)
2010 Dr. Nancy A. Moran (Biology of Symbiosis)
CSHL 78th Cold Spring Harbor Symposium on Quantitative Biology

Immunity & Tolerance

Organized by:
- Michel Nussenzweig, HHMI / The Rockefeller University
- Anne O’Garra, MRC National Institute for Medical Research, UK
- Stephen Smale, UCLA School of Medicine
- David Stewart & Bruce Stillman, Cold Spring Harbor Laboratory

Registration, abstract submission and further information:
http://www.cshl.edu/meetings
email: meetings@cshl.edu
phone: 516-367-8346
fax: 516-367-8845

Topics
- Stem cells and cell fate decisions
- Regulation of immune cell development
- Antigen receptor gene assembly and modification
- Signal transduction
- Regulation of lymphocyte function
- Innate immune response and inflammation
- Adaptive immunity
- Mucosal immunity

May 29 - June 3, 2013
Poster abstracts due: April 15

Organic specific immunity
- Immune regulation and tolerance
- Autoimmunity and allergy
- Immunity and cancer
- Pathogen-immune system interactions
- Vaccine development
- Novel strategies to engineer/harness immunity

Susan Pierce, National Institutes of Health
Hidde Ploegh, Whitehead Institute for Biomedical Research
Jonathan Powell, Johns Hopkins University School of Medicine
Fiona Powrie, University of Oxford, UK
Cristina Rada, MRC Laboratory of Molecular Biology, UK
Klaus Rajewsky, Harvard Medical School
Anjana Rao, LaJolla Institute for Allergy & Immunology
Laith Ramakrishnan, University of Washington
David Rauter, University of California, Berkeley
Jeffrey Ravetch, The Rockefeller University
Ellen Rothenberg, California Institute of Technology
Alexander Rudensky, Memorial Sloan Kettering Cancer Center
Federica Sallusto, Institute for Research in Biomedicine, Switzerland
David Schatz, HHMI/Yale Medical School
Robert Schreiber, Washington University School of Medicine
Harinder Singh, Genentech
Stephen Smale, UCLA School of Medicine
Tadatoshi Taniguchi, University of Tokyo, Japan
Alexander Tarakhovsky, The Rockefeller University
Craig Thompson, Memorial Sloan Kettering Cancer Center
Carola Vinuesa, Australian National University, Australia
Ulrich von Andrian, Harvard Medical School
Harald von Boehmer, Dana-Farber Cancer Institute
Bruce Walker, Ragon Institute of MGH, MIT and Harvard
Hedda Wardenmann, Max Planck Institute for Infection Biology, Germany
Art Weiss, HHMI/University of California, San Francisco
Irving Weissman, Stanford University
Wayne Yokoyama, HHMI/Washington University

Raif Ahmed, Emory University School of Medicine
Shizu Akira, Osaka University, Japan
James Allison, HHMI/Memorial Sloan Kettering Cancer Center
Frederick Alt, HHMI/Children’s Hospital
David Baltimore, California Institute of Technology
Yasmine Belkaid, National Institutes of Health
Albert Bendelac, University of Chicago
Zami Ben-Sasson, Hebrew University Medical School, Jerusalem, Israel
Christophe Benoist, Harvard Medical School
Pamela Bjorkman, HHMI/California Institute of Technology
Menrad Busslinger, Research Institute of Molecular Pathology, Austria
Doreen Carroll, College of Life Sciences, Dundee, UK
Rafael Casellas, National Institutes of Health
Jean-Laurent Casanova, The Rockefeller University
Ajay Chawla, University of California, San Francisco
Max Cooper, Emory University
Peter Cresswell, HHMI/Yale Medical School
Shane Crotty, La Jolla Institute for Allergy and Immunology
Mark Davis, HHMI/Stanford University School of Medicine
Richard Flavell, Yale University School of Medicine
Frederic Geissman, Centre for Molecular & Cellular Biology of Inflammation
Sankar Ghosh, Columbia University College of Physicians & Surgeons
Rudolf Grosschedl, Max Planck Institute of Immunobiology, Germany
William Jacobs, HHMI/Albert Einstein College of Medicine
John Kappler, HHMI/National Jewish Health
Lewis Lanier, University of California, San Francisco
Dan Littman, HHMI/NYU School of Medicine
Richard Locksley, University California San Francisco
Tak Mak, Ontario Cancer Institute, Canada
Philippa Marrack, National Jewish Center, Denver
Diane Mathis, Harvard Medical School
Ruslan Medzhitov, HHMI/Yale University
Miriam Merad, Mount Sinai Hospital School of Medicine
Kenneth Murphy, HHMI/Washington University
Cornelis Muris, University of California, San Diego
Gioacchino Natoili, European Institute of Oncology, Italy
Michel Nussenzweig, HHMI/Rockefeller University
Anne O’Garra, MRC National Institute for Medical Research, UK
Eric Panter, Memorial Sloan-Kettering Cancer Center
M. Virginia Pascual, Baylor Institute for Immunology Research
William Paul, National Institutes of Health/NIAID

Registration, abstract submission and further information:
http://www.cshl.edu/meetings
email: meetings@cshl.edu
phone: 516-367-8346
fax: 516-367-8845

Image credit: James Duffy & James Whitaker
Poster credit: Catherine Dougherty
The European Cancer Congress 2013: The largest platform for practice-changing data in Europe

The recognised multidisciplinary setting of the Congress is once again providing ideal surroundings for participants to leverage knowledge, promote education and build awareness about oncology - placing the patient at the heart of all discussions.

The renowned quality of the Scientific Programme will guarantee a comprehensive, stimulating, rigorous and highly educational scientific experience, irrespective of your role or focus in oncology.

Abstract Submission Closing Date: 17 April 2013
eccamsterdam2013.ecco-org.eu

- Recognised Impact
- Global Visibility
- Top Quality Content
- No Limits

WORKSHOPS

Latin American eScience Workshop 2013

Sponsored jointly by Microsoft Research and FAPESP
May 13 – 15, 2013 – São Paulo, Brazil

In Brazil, researchers have been working together to increase our understanding of tropical ecosystems, human impact on the environment, biogenetics, and biodiversity. These efforts are providing new opportunities to improve our capabilities in data-intensive research and strengthen the eScience research community. From May 13 to 15, 2013, we will host a special eScience Workshop in the city of São Paulo, Brazil. The event will bring together more than 150 participants, including students and researchers from all over the world, to explore collaboration and research opportunities in areas such as environmental sciences, bioenergy, biodiversity, health and digital humanities. More information about the workshop and the registration can be found at the workshop website.

http://www.fapesp.br/eventos/latam2013
Summer/Fall Meetings

Meeting dates

**Wiring the Brain**
July 18 - 22

**Metabolic Signaling & Disease: From Cell to Organism**
August 13 - 17

**Eukaryotic mRNA Processing**
August 20 - 24

**Mechanisms of Eukaryotic Transcription**
August 27 - 31

**Behavior & Neurogenetics of Nonhuman Primates**
September 6 - 9

**Eukaryotic DNA Replication & Genome Maintenance**
September 9 - 13

**Microbial Pathogenesis & Host Response**
September 17 - 21

---

**Fall Courses**

Course dates

**Programming for Biology**
October 14 - 29

**X-Ray Methods in Structural Biology**
October 14 - 29

**Computational & Comparative Genomics**
November 6 - 12

---

**CSH Asia 2013 Meetings**

Meetings dates

**Metabolism, Obesity & Obesity-associated Diseases**
May 20 - 24

**Plant Cell & Developmental Biology**
June 17 - 21

**Yersinia 11**
June 24 - 28

**Summer School: Computational & Cognitive Neuroscience**
July 6 - 24

**New Advances in Optical Imaging of Live Cells & Organisms**
August 20 - 23

**Cell Signaling in Metabolism, Inflammation & Cancer**
September 2 - 6

**Molecular Basis of Aging & Disease**
September 9 - 13

---

**Frontiers in Bioinformatics & Computational Biology**
September 23 - 27

**Genetic, Genomic, & Translational Studies of Human Leukemia**
October 7 - 11

**CSHA/ISSCR Joint Meeting on Stem Cells in Science & Medicine**
October 14 - 17

**Development, Function & Disease of Neural Circuits**
October 21 - 25

**Tumor Immunology & Immunotherapy**
October 28 - November 1

**Nuclear Receptors & Metabolism**
November 4 - 8

**Bacterial Infection & Host Defense**
November 18 - 22
Faculty Position
Department of Cellular and Structural Biology
School of Medicine

Applications are invited for a FACULTY POSITION in the Department of Cellular and Structural Biology, School of Medicine, at the University of Texas Health Science Center at San Antonio.

We seek applicants interested and experienced in teaching human histology courses, potentially coupled with an active research program in the area of cell biology. The ideal applicant will have training and experience in teaching human histology such that he/she could rapidly move into a course leadership role. Success in research, evidenced by publications and extramural support, would be an asset. Applicants who would complement current research strengths in the department, which include cancer biology, cell and organelle biology, DNA repair and mutagenesis, genetics and genomics, inflammation and disease, molecular biology of aging and age-related diseases, neurobiology and stem cell and developmental biology, are particularly encouraged to apply. Rank and tenure status will be dependent upon qualifications. Candidates should have a PhD, MD, DDS, or DVM. The Department has a rich history of teaching and research excellence and innovation. Priority will be given to applicants that show promise of enhancing these traditions. Potential applicants are invited to visit our web site http://www.uthscsa.edu/csb/.

The UT Health Science Center at San Antonio is home to the Nathan Shock Center for Excellence in Biology of Aging, an NCI-designated Cancer Center, an NIH-funded Clinical Translational Science Award and the Greehey Children’s Cancer Research Institute. The UT Health Science Center is designated an Hispanic-Serving Institution. This is a wonderful opportunity for a new faculty member with an institutional administration focused on research, education and clinical care. The UT Health Science Center at San Antonio is a Tier One research institution located in the Northwest region of San Antonio and sits as a gateway to the picturesque Texas Hill Country. San Antonio is a dynamic and multicultural city with much to offer including an attractive cost-of-living.

Interested candidates should submit an application electronically as a single PDF comprised of their complete curriculum vitae, a statement of teaching philosophy and research interests, and a list of 4 to 5 references with contact information. Up to 3 high impact publications can be included in the application materials. Applications can be submitted to (email: FacsearchCSB@uthscsa.edu) and will be reviewed starting immediately, until the position is filled.

The University of Texas Health Science Center at San Antonio is An Equal Employment Opportunity/Affirmative Action Employer and is committed to diversity among its faculty, staff and students. All faculty appointments are designated as security sensitive positions.

---

VCU

The Department of Anatomy and Neurobiology, School of Medicine, Virginia Commonwealth University is offering two tenure-track/tenured positions (F19890/F56750) at the Associate or full Professor level. The Department currently has 18 full-time neuroscience faculty. Internationally recognized research programs in glial cell biology, neuroplasticity, and traumatic brain injury are supported by substantial extramural funding. Additionally, the Department/VCU offers:

• An advanced, NIH-supported, bioimaging core housed within the department
• Multiple, staffed core facilities/centers (Center for Molecular Imaging, Flow Cytometry Resource Core, Chemical and Proteomic Mass Spectrometry Facility, Transgenic/Knock-out Mouse Facility, Cytogenetics Diagnostic Facility, and others)
• Positions that are supported by state funds
• Attractive and competitive salary and start-up funds

There is a large, active, and highly collegial neuroscience community at VCU that offers outstanding opportunities for collaborations with faculty in both basic science and clinical departments. Applicants should have an active and productive research program that complements the research directions of the department, and which is supported by significant extramural funding. The successful candidate will contribute to graduate and/or professional student teaching in either gross anatomy, histology, or neuroscience. Applicants should possess a PhD, MD, or DDS degree, or equivalent, and be committed to working with and fostering the development of a diverse faculty, staff, and student population or a commitment to do so as a faculty member at VCU. Review of the applications will begin immediately and the positions will remain open until filled.

Interested candidates should send a curriculum vitae, a one page letter of intent outlining their research and scholarly accomplishments, and the name, address, telephone number, and email address of three references. Application materials must be electronically submitted to anatrecruit@vcu.edu.

Virginia Commonwealth University is an Equal Opportunity/Affirmative Action Employer. Women, minorities, and persons with disabilities are encouraged to apply.

---

Science Careers

Science Careers is dedicated to opening new doors and providing timely answers to the career questions that matter to you.

Science Careers Forum:
» Relevant Career Topics
» Timely Advice and Answers
» Community, Connections, and More!

Visit the forum and join the conversation today!